Tailor-made proteins are playing a pivotal role in a plethora of different applications such as in biomedicine, in the chemical as well as food industry or in cosmetics. In a commonly used definition, the discipline ‘Protein Engineering’ describes the (more or less) targeted modification of already existing proteins, for instance, to enhance their biophysical or biochemical properties, whereas ‘Protein Design’ aims at generating artificial proteins displaying novel forms and functionalities. Presently engineered proteins affect the daily life of most of us – in fact with many of us often not even being aware of it. For example, engineered enzymes are exploited in order to process food or as ingredients in laundry detergents. A more obvious field in which protein engineering has made a tremendous impact is medicine. Many diagnostic reagents as well as the vast majority of biological therapeutics are engineered in one way or the other. A very prominent example of biomedical modalities are therapeutic antibodies. As of now, more than 100 antibodies have been approved by healthcare authorities. The vast majority – if not all – are artificially optimized molecules, for instance by humanization, by removal of sequence liabilities or by changes that improve the affinity for a cognate antigen. Furthermore, immunoglobulin-based derivatives that were engineered in a more sophisticated way are entering the clinical pipeline and the global market. Bispecific antibodies, for instance, bind two different antigens simultaneously thereby enabling to address the multifaceted nature of many diseases more adequately. Other approaches, such as antibody drug conjugates or prodrugs, aim at specifically activating the toxic properties of the therapeutic directly at the site of disease e.g. at the tumor tissue or the malignant cell to improve patient safety. Besides antibodies, also other protein-based molecules have proven to be of utmost relevance regarding therapeutic or diagnostic applications. These include engineered enzymes or proteins that can be found in nature but that are optimized or tailor-made to fulfill a specific function. Within the past years the COVID-19 pandemic has shown that protein engineering is inevitable to understand this and other diseases but also to generate effective therapeutics and vaccines at an unprecedented pace. The recent developments in protein structure prediction and computational design promise to speed up these exciting developments even further. Therefore, we feel it is timely to place a special focus on this topic.
This Highlight Issue of Biological Chemistry is dedicated to novel trends in the field of Protein Engineering and Protein Design. Here, we provide a compilation of cutting-edge articles covering various aspects of tailor-made proteins ranging from antibody hit discovery via multispecific antibodies, antibody fusion proteins as well as prodrug approaches to antibody drug conjugates. Additionally, scaffold proteins, i.e. naturally occurring proteins engineered to comprise novel binding functionalities, as well as modular peptide binders as complementary modalities are discussed. The portfolio continues with insights on design principles for the generation of photo-controllable proteins. Finally, also the ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) found its way into this Highlight Issue. These excellent, peer-reviewed contributions nicely show the different approaches taken in the field and reflect the broad applicability of protein engineering and design.
-
Author contributions: Both authors of this article contributed equally to this Guest Editorial.
-
Research funding: None declared.
-
Conflict of interest statement: The authors declare that this work was conducted in the absence of any conflict of interest.
© 2022 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Highlight: Protein Engineering & Design
- Protein engineering & design: hitting new heights
- Antibody display technologies: selecting the cream of the crop
- In vitro evolution of myc-tag antibodies: in-depth specificity and affinity analysis of Myc1-9E10 and Hyper-Myc
- Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
- Trispecific antibodies produced from mAb2 pairs by controlled Fab-arm exchange
- EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing
- Modular peptide binders – development of a predictive technology as alternative for reagent antibodies
- Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
- Structural basis of Alzheimer β-amyloid peptide recognition by engineered lipocalin proteins with aggregation-blocking activity
- A guide to designing photocontrol in proteins: methods, strategies and applications
- Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein
Artikel in diesem Heft
- Frontmatter
- Highlight: Protein Engineering & Design
- Protein engineering & design: hitting new heights
- Antibody display technologies: selecting the cream of the crop
- In vitro evolution of myc-tag antibodies: in-depth specificity and affinity analysis of Myc1-9E10 and Hyper-Myc
- Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
- Trispecific antibodies produced from mAb2 pairs by controlled Fab-arm exchange
- EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing
- Modular peptide binders – development of a predictive technology as alternative for reagent antibodies
- Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
- Structural basis of Alzheimer β-amyloid peptide recognition by engineered lipocalin proteins with aggregation-blocking activity
- A guide to designing photocontrol in proteins: methods, strategies and applications
- Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein